Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Google’s search engine fields 6.3 million queries every second. But the results it dishes up are far from perfect.

SoftBank disclosed a 20.45M share position in PacBio (PACB) and 14.67M share position in Recursion Pharmaceuticals (RXRX) in a regulatory ...

Look closely at this image, stripped of its caption, and join the moderated conversation about what you and other students see. By The Learning Network Look closely at this image, stripped of ...

🌳 This repository is dedicated to the Binary Search Tree (BST) data structure, featuring a comprehensive demo of all its functionalities including insertion, deletion, search, and traversal ...